Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia’s year-end report for January to December 2025 outlines progress across its pipeline of antibody-based drug candidates targeting cancer and severe immunological diseases. The report highlights the company’s continued development efforts and strategic partnerships around assets like nadunolimab, CAN14, CANxx and CAN10, underscoring its ambition to strengthen its position in innovative biologic therapies despite the absence of detailed financial figures or trial outcomes in the translated summary.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK7.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological disorders and other life-threatening or serious, debilitating diseases. Its pipeline includes several drug candidates such as nadunolimab, CAN14, CANxx and CAN10, aimed at delivering new and improved therapeutic options in these areas.
Average Trading Volume: 3,629,182
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.26B
See more data about CANTA stock on TipRanks’ Stock Analysis page.